-
You must submit the settlement Proof form attached below, in order to participate in this settlement. There is a strict deadline of November 6, 2018 by which all claims must be submitted. The instructions for submitting are included in the Proof and the Notice files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDERS FOUNDATION, INC.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
August 8, 2018 - The court preliminarily approved the settlement.
August 2, 2018 - A stipulation of settlement was filed by the parties.
June 14, 2017 - The court denied defendants' motion to dismiss.
February 2, 2017 - A motion to dismiss the amended consolidated complaint was filed.
December 12, 2016 - An amended consolidated complaint was filed.
July 12, 2016 - An investor in shares of Juno Therapeutics Inc (NASDAQ: JUNO) filed a lawsuit in the U.S. District Court for the Western District of Washington over alleged violations of Federal Securities Laws by Juno Therapeutics Inc in connection with certain allegedly false and misleading statements made between June 4, 2016 and July 7, 2016.
According to the complaint the plaintiff alleges on behalf of purchasers of Juno Therapeutics Inc (NASDAQ: JUNO) common shares between June 4, 2016 and July 7, 2016 , that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between June 4, 2016 and July 7, 2016 the defendants materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015 and that these omissions led Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death.
On July 7, 2016, Juno Therapeutics Inc announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial. Juno Therapeutics Inc said that the clinical hold was initiated after two patient deaths one week earlier, which followed the recent addition of fludarabine to the pre-conditioning regimen.
Shares of Juno Therapeutics Inc (NASDAQ: JUNO) declined on July 12, 2016 to as low as $27.15 per share.